A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have failed (progressive disease or intolerance) previous oxaliplatin-based and fluoropyrimidine-based chemotherapies.
Epistemonikos ID: 951020ce19a6cd8f6303fea360c608c74a118c25
First added on: May 04, 2024